Inventiva S.A. (IVA) Q4 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you, operator, and welcome to everybody to this full year 2022 financial results. As usual, I will be making with my colleague forward-looking statements, so please have a look at the regulatory documentation that is available on our website. In terms of speakers today, I'm very happy, as usual, to have Pierre with us, our CSO and co-founder. michael our cmo will go through an update of our three important clinical trials with with an ephemeral of course the phase three but also two phase two that are ongoing and then john will conclude the presentation with an update on the financials of course at the end of the session you we will have a q a session So let me give you, first of all, some highlights for the full year. So let's start with our lead program, NANI, in NASH, and start with Native 3, where we've been, I would say, very happy to work and extend, to develop the Phase 3 in 23 countries. And now we have more than 350 clinical sites that are active and more than 300 that have screened at least a patient. We have throughout the year, and we continue to do so, implemented a series of measures to boost enrollment. And I would say that this continues throughout 2023. We've done many things and we're very Proud of those and grateful to our team. We have reviewed and implemented a new process to speed up how biopsies are analyzed. We have trained sites. We have put in place incentives. We have included site networks which are specialized with a strong NASH expertise. And we also have closed sites that were not performing to our expectations. have developed patient material including opening recently the patient website we have provided support to prescreening activities to sites including providing a screening algorithm to better identify the patients we are w...